Authors
Latest:
Dr Oveisi on the Potential Role of Bispecific Antibodies in Multiple MyelomaDavid R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.
Latest:
Education Is a Personal MissionSantosh Saraf, MD, changed his major 3 times as an undergrad at Penn State University, bouncing from premed to mathematics to marine biology before settling back into medicine.
Latest:
Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple MyelomaNeha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.
Latest:
Dr. Yuan on Ongoing Research in Patients With TNBC According to Pathologic ResponseYuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.
Latest:
Unmet Needs and Future of Lower-Risk MDSThe panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
Latest:
Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.
Latest:
Key Takeaways From DiscussionPhysicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.
Latest:
Key Takeaways For Treating Patients Diagnosed With CholangiocarcinomaProvider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Latest:
Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid TumorsBenjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple MyelomaDouglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.
Latest:
What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.
Latest:
Future Management of Uveal MelanomaThe next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Latest:
Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple MyelomaTerri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.
Latest:
Novel Therapies Under Study for Triple-Class Refractory Multiple MyelomaNovel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.
Latest:
Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship StoriesSangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Latest:
Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 VaccinesRenold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.
Latest:
Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal CancerJoshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.
Latest:
Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia IntensivaNidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.
Latest:
Dr Possik on the Importance of Diversity and Equity in Melanoma ResearchPatricia A. Possik, PhD, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research.
Latest:
Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and BastosOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung CancerPaul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.
Latest:
Dr Zeidan on Classification and Treatment Updates in MDSAmer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.
Latest:
Dr Lin on Defining Biomarker-Based Treatment Approaches in NSCLCEdwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.
Latest:
Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the ProstateBenjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.
Latest:
Dr. Meyer on Standard Treatment Options in Cardiac AngiosarcomaChristian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.
Latest:
Dr. Choudhri on the Impact of Artificial Intelligence in Cancer CareAjay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.
Latest:
Dr. Narla on Advances Made With Precision Medicine in OncologyGoutham Narla, MD, PhD, discusses advances made with precision medicine in oncology.
Latest:
Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast CancerNicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple MyelomaJeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.
